Doximity (NYSE:DOCS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Doximity (NYSE:DOCS) had its price target lifted by analysts at Royal Bank Of Canada from $28.00 to $34.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price objective indicates a potential upside of 6.99% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. Weiss Ratings upgraded shares of Doximity from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, October 6th. Barclays upped their price objective on shares of Doximity from $20.00 to $27.00 and gave the company an “equal weight” rating in a research note on Friday, August 21st. Piper Sandler reaffirmed an “overweight” rating and set a $47.00 price objective (up from $42.00) on shares of Doximity in a report on Friday, August 7th. Wolfe Research upgraded Doximity to an “outperform” rating in a research report on Thursday, August 13th. Finally, Truist Financial boosted their target price on Doximity from $19.00 to $24.00 and gave the company a “hold” rating in a report on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $30.27.

Doximity Stock Down 4.2%

Doximity stock traded down $1.40 during midday trading on Friday, reaching $31.78. The company’s stock had a trading volume of 2,332,285 shares, compared to its average volume of 3,881,142. The company has a market cap of $5.66 billion, a P/E ratio of 37.31, a P/E/G ratio of 27.12 and a beta of 1.29. The business has a 50-day simple moving average of $28.95 and a 200-day simple moving average of $25.55. Doximity has a fifty-two week low of $17.15 and a fifty-two week high of $58.24.

Doximity (NYSE:DOCS) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.13. The business had revenue of $156.62 million during the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%. The company’s revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.36 earnings per share. As a group, equities analysts forecast that Doximity will post 0.74 earnings per share for the current year.

Insider Transactions at Doximity

In related news, Director Kira Wampler sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $32.89, for a total transaction of $65,780.00. Following the transaction, the director owned 27,923 shares of the company’s stock, valued at $918,387.47. This trade represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Phoebe Yang sold 1,290 shares of the business’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $26.71, for a total value of $34,455.90. Following the completion of the transaction, the director owned 24,744 shares in the company, valued at $660,912.24. This trade represents a 4.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 13,750 shares of company stock worth $386,310. Company insiders own 31.80% of the company’s stock.

Institutional Investors Weigh In On Doximity

Several large investors have recently modified their holdings of the stock. Carmignac Gestion lifted its stake in shares of Doximity by 127.8% in the first quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock valued at $100,480,000 after purchasing an additional 2,418,971 shares during the period. Assenagon Asset Management S.A. acquired a new position in Doximity during the third quarter worth about $28,858,000. Swedbank AB grew its position in Doximity by 1,147.9% during the first quarter. Swedbank AB now owns 1,010,559 shares of the company’s stock worth $23,546,000 after buying an additional 929,576 shares during the period. Renaissance Technologies LLC grew its position in Doximity by 29.4% during the first quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock worth $71,292,000 after buying an additional 694,300 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Doximity by 24.7% in the second quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock valued at $65,022,000 after buying an additional 621,464 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity News Summary

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported fiscal Q2 2027 revenue of $174.5 million and earnings of $0.36 per share, beating estimates. It also forecast Q3 revenue of $195–$196 million and fiscal 2027 revenue of $678–$683 million, both above consensus. Management cited record engagement, a 51% adjusted EBITDA margin, and more than 190 health systems purchasing its AI suite. Fiscal 2027 Q2 results
• Positive Sentiment: Needham reaffirmed its Buy rating and $41 price target, signaling potential upside from the current share price. Needham analyst rating
• Negative Sentiment: The stock’s weak response contrasts with the earnings beat. Quarterly revenue grew 3.6% year over year, while EPS declined from $0.45 a year earlier to $0.36—potentially raising concerns about the pace of growth and earnings trends. Doximity quarterly results and stock reaction
• Negative Sentiment: Several law firms highlighted a securities class action and the November 16 lead-plaintiff deadline. The complaint alleges that Doximity misrepresented the contribution of its Newsfeed advertising product to growth; these claims have not been proven, but the litigation may add investor uncertainty. Class action deadline notice
• Neutral Sentiment: A director sold 2,000 shares under a pre-arranged Rule 10b5-1 plan. The transaction was relatively small and scheduled in advance, so it may have limited significance on its own. Director share sale

About Doximity

Doximity, Inc operates a digital platform designed for medical professionals in the United States. Its network connects physicians, nurse practitioners, physician assistants, pharmacists and other healthcare professionals, providing tools for professional communication, collaboration and career development.

The company offers services including secure messaging, telehealth, digital faxing, physician scheduling and professional networking. Doximity also provides medical news and educational content, as well as recruiting and job-search resources for healthcare professionals.

Doximity generates additional revenue through digital marketing and engagement solutions for pharmaceutical companies, healthcare organizations and health systems.